Loading…
Loading…
EQUITY / NASDAQ · XNCM
Cellyan Biotechnology Co., Ltd Class A Ordinary Shares
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2024 – 03/31/2025 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.1095 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 0.1095 USD · Volume 259,835
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
3 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2024 – 03/31/2025 · Units
| Metric | 2025 / Year end | 2024 / Year end | Change |
|---|---|---|---|
| Revenue | 20,313,818 USD | 16,688,364 USD | +21.72% |
| Operating profit | -2,284,587 USD | -1,954,442 USD | — |
| Net income | -27,056 USD | 1,329,717 USD | -102.03% |
| Operating cash flow | 569,214 USD | -394,330 USD | — |
| Cash and cash equivalents | 748,721 USD | 619,575 USD | +20.84% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2025 / Year end04/01/2024 – 03/31/2025ConsolidatedUnits · USD | 2024 / Year end04/01/2023 – 03/31/2024ConsolidatedUnits · USD | 2023 / Year end04/01/2022 – 03/31/2023ConsolidatedUnits · USD |
|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 748,721 USD | 619,575 USD | — |
| Financing cash flowCash flow statement | 1,995,114 USD | 537,315 USD | -1,155,671 USD |
| Gross profitIncome statement | 2,415,159 USD | 3,558,665 USD | 2,738,925 USD |
| Investing cash flowCash flow statement | -2,454,963 USD | -40,796 USD | -132,095 USD |
| Net incomeIncome statement | -27,056 USD | 1,329,717 USD | 998,196 USD |
| Operating cash flowCash flow statement | 569,214 USD | -394,330 USD | 1,727,079 USD |
| Operating profitIncome statement | -2,284,587 USD | -1,954,442 USD | -1,791,361 USD |
| RevenueIncome statement | 20,313,818 USD | 16,688,364 USD | 12,555,991 USD |
| Total assetsBalance sheet | 9,417,276 USD | 8,667,228 USD | — |
| Total equityBalance sheet | 4,989,769 USD | 4,253,659 USD | 585,242 USD |
| Total liabilitiesBalance sheet | 4,427,507 USD | 4,413,569 USD | — |
| Report source | Open report ↗ Published: 08/14/2025 | Open report ↗ Published: 08/14/2025 | Open report ↗ Published: 08/14/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.